Maeve A. Lowery

16.7k total citations · 1 hit paper
141 papers, 3.5k citations indexed

About

Maeve A. Lowery is a scholar working on Oncology, Surgery and Cancer Research. According to data from OpenAlex, Maeve A. Lowery has authored 141 papers receiving a total of 3.5k indexed citations (citations by other indexed papers that have themselves been cited), including 105 papers in Oncology, 56 papers in Surgery and 53 papers in Cancer Research. Recurrent topics in Maeve A. Lowery's work include Pancreatic and Hepatic Oncology Research (69 papers), Cancer Genomics and Diagnostics (49 papers) and Cholangiocarcinoma and Gallbladder Cancer Studies (35 papers). Maeve A. Lowery is often cited by papers focused on Pancreatic and Hepatic Oncology Research (69 papers), Cancer Genomics and Diagnostics (49 papers) and Cholangiocarcinoma and Gallbladder Cancer Studies (35 papers). Maeve A. Lowery collaborates with scholars based in United States, Ireland and Canada. Maeve A. Lowery's co-authors include Eileen M. O’Reilly, Kenneth H. Yu, Marinela Capanu, David S. Klimstra, Ghassan K. Abou‐Alfa, David P. Kelsen, Zsofia K. Stadler, Peter J. Allen, Jinru Shia and Erin Salo‐Mullen and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer.

In The Last Decade

Maeve A. Lowery

136 papers receiving 3.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Comprehensive Molecular Profiling of Intrahepatic and Extrahepatic Cholangiocarcinomas: Potential Targets for Intervention

2018 369 citations Maeve A. Lowery, Emmet Jordan et al. Clinical Cancer Research profile →

Peers

Countries citing papers authored by Maeve A. Lowery

Since Specialization

Citations

This map shows the geographic impact of Maeve A. Lowery's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Maeve A. Lowery with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Maeve A. Lowery more than expected).

Fields of papers citing papers by Maeve A. Lowery

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Maeve A. Lowery. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Maeve A. Lowery. The network helps show where Maeve A. Lowery may publish in the future.

Co-authorship network of co-authors of Maeve A. Lowery

This figure shows the co-authorship network connecting the top 25 collaborators of Maeve A. Lowery. A scholar is included among the top collaborators of Maeve A. Lowery based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Maeve A. Lowery. Maeve A. Lowery is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	First-line pembrolizumab plus chemotherapy for advanced HER2-negative gastric or gastroesophageal junction adenocarcinoma: Health-related quality of life from the randomized phase III KEYNOTE-859 trial 2025 ·European Journal of Cancer ·Maeve A. Lowery, Lucjan Wyrwicz, Do‐Youn Oh, Kai‐Keen Shiu, Patricio Yañez, Yuxian Bai, Min‐Hee Ryu, Jeeyun Lee, Fernando Rivera, Gustavo Vasconcelos Alves, Marcelo Garrido, (unknown), Jin Li, Timuçin Çil, Felipe José Silva Melo Cruz, Shukui Qin, (unknown), Adriana Valderrama, Sonal Bordia, Sun Young Rha	0
2	Pembrolizumab with trastuzumab and chemotherapy for HER2-positive advanced gastric cancer: health-related quality-of-life analysis from the randomized KEYNOTE-811 trial 2025 ·ESMO Open ·Yelena Y. Janjigian, Akihito Kawazoe, Jianming Xu, Sara Lonardi, J-P. Metges, (unknown), Lin Shen, (unknown), (unknown), Maeve A. Lowery, Adriana Valderrama, (unknown), Ka Wan Li, Chie‐Schin Shih, Sun Young Rha	0
3	Pembrolizumab (pembro) + chemotherapy (chemo) for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: Updated results from the KEYNOTE-859 study. 2024 ·Journal of Clinical Oncology ·Sun Young Rha, Lucjan Wyrwicz, (unknown), Yuxian Bai, Min‐Hee Ryu, Jeeyun Lee, Fernando Rivera, Gustavo Vasconcelos Alves, Marcelo Garrido, Kai‐Keen Shiu, M. Fernández, Jin Li, Maeve A. Lowery, Timuçin Çil, Felipe José Silva Melo Cruz, Do‐Youn Oh, Lina Yin, Sonal Bordia, Pooja Bhagia, Shukui Qin	5
4	Modifiable Risk Factors and Risk of Colorectal and Endometrial Cancers in Lynch Syndrome: A Systematic Review and Meta-Analysis 2024 ·JCO Precision Oncology ·Robert Power, (unknown), Imelda Parker, David Gallagher, Maeve A. Lowery, Karen A. Cadoo	7
5	SO-2 Quantitative risk-benefit assessment of ivosidenib compared to placebo in patients with IDH1-mutated intrahepatic cholangiocarcinoma: Phase 3 ClarIDHy trial 2023 ·Annals of Oncology ·Juan W. Valle, Ghassan K. Abou‐Alfa, Robin Kate Kelley, Maeve A. Lowery, Rachna T. Shroff, Yunyi Bian, Gaëlle Saint‐Hilary, Hui Liu, Zhongzhao Teng, Hua Zhang, Camelia Gliser, Arndt Vogel, Milind Javle	0
6	Moving the Needle on Precision Medicine in Pancreatic Cancer 2022 ·Journal of Clinical Oncology ·Grainne M. O’Kane, Maeve A. Lowery	24
7	Advances in the curative management of oesophageal cancer 2021 ·British Journal of Cancer ·Jarlath Bolger, Claire L. Donohoe, Maeve A. Lowery, John V. Reynolds	54
8	DNA Damage Repair Deficiency in Pancreatic Ductal Adenocarcinoma: Preclinical Models and Clinical Perspectives 2021 ·Frontiers in Cell and Developmental Biology ·(unknown), (unknown), (unknown), Maeve A. Lowery, Naomi Walsh	11
9	Frequency, Morbidity, and Mortality of Bone Metastases in Advanced Hepatocellular Carcinoma 2018 ·Journal of the National Comprehensive Cancer Network ·James J. Harding, Ghaith Abu‐Zeinah, Joanne F. Chou, Dwight H. Owen, Michele Ly, Maeve A. Lowery, Marinela Capanu, Richard Kinh Gian, Nancy E. Kemeny, Eileen M. O’Reilly, Leonard B. Saltz, Ghassan K. Abou‐Alfa	39
10	Brain Metastases in Pancreatic Ductal Adenocarcinoma: Assessment of Molecular Genotype–Phenotype Features—An Entity With an Increasing Incidence? 2018 ·Clinical Colorectal Cancer ·Emmet Jordan, Maeve A. Lowery, Olca Baştürk, Peter J. Allen, Kenneth H. Yu, Viviane Tabar, Kathryn Beal, Diane Reidy‐Lagunes, Yoshiya Yamada, Yelena Y. Janjigian, Ghassan K. Abou‐Alfa, Eileen M. O’Reilly	14
11	Incidence, Management, and Implications of Visceral Thrombosis in Pancreatic Ductal Adenocarcinoma 2018 ·Clinical Colorectal Cancer ·(unknown), (unknown), Richard Kinh Gian, Kenneth H. Yu, Maeve A. Lowery, Anna M. Varghese, Eileen M. O’Reilly	18
12	Systemic Chemotherapy Combined with Resection for Locally Advanced Gallbladder Carcinoma: Surgical and Survival Outcomes 2017 ·Journal of the American College of Surgeons ·John M. Creasy, Debra A. Goldman, Vikas Dudeja, Maeve A. Lowery, Andrea Cercek, Vinod P. Balachandran, Peter J. Allen, Ronald P. DeMatteo, T. Peter Kingham, Michael I. D’Angelica, William R. Jarnagin	53
13	Case report: primary acinar cell carcinoma of the liver treated with multimodality therapy 2017 ·Journal of Gastrointestinal Oncology ·Emmet Jordan, Olca Baştürk, Jinru Shia, David S. Klimstra, William Alago, Michael I. D’Angelica, Ghassan K. Abou‐Alfa, Eileen M. O’Reilly, Maeve A. Lowery	6
14	Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinoma 2017 ·European Journal of Cancer ·Maeve A. Lowery, David P. Kelsen, Marinela Capanu, (unknown), Jonathan W. Lee, Zsofia K. Stadler, Malcolm J. Moore, Hedy L. Kindler, Talia Golan, Amiel Segal, Hannah Maynard, Ellen Hollywood, Mary Ellen Moynahan, Erin Salo‐Mullen, Richard Kinh Gian, Alice P. Chen, Kenneth H. Yu, Laura H. Tang, Eileen M. O’Reilly	123
15	Clinical and Molecular Analysis of Adenosquamous Carcinoma of the Pancreas 2016 ·JOP, journal of the pancreas ·Emmet Jordan, Olca Baştürk, Steven D. Leach, David S. Klimstra, Peter J. Allen, Michael F. Berger, Gokce Askan, Christine A. Iacobuzio–Donahue, Kenneth H. Yu, (unknown), Maeve A. Lowery	1
16	Pancreas Adenocarcinoma: Ascites, Clinical Manifestations, and Management Implications 2016 ·Clinical Colorectal Cancer ·(unknown), Joanne Chou, Marinela Capanu, Maeve A. Lowery, Kenneth H. Yu, Eileen M. O’Reilly	25
17	Systemic therapy for biliary cancers 2016 ·Chinese Clinical Oncology ·Emmet Jordan, Ghassan K. Abou‐Alfa, Maeve A. Lowery	11
18	Novel Therapeutics for Pancreatic Adenocarcinoma 2015 ·Hematology/Oncology Clinics of North America ·Maeve A. Lowery, Eileen M. O’Reilly	14
19	Pharmacogenomic Modeling of Circulating Tumor and Invasive Cells for Prediction of Chemotherapy Response and Resistance in Pancreatic Cancer 2014 ·Clinical Cancer Research ·Kenneth H. Yu, (unknown), Manuel Hidalgo, Ghassan K. Abou‐Alfa, Maeve A. Lowery, Leonard B. Saltz, (unknown), (unknown), Brandon Cooper, (unknown), Mariola Sadowska, Eileen M. O’Reilly	41
20	Genomics and pharmacogenomics of pancreatic adenocarcinoma 2011 ·The Pharmacogenomics Journal ·Maeve A. Lowery, Eileen M. O’Reilly	13

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact